Metraipolis › archive › dc_445ea9d8537b

Characterizing clinical toxicity in cancer combination therapies — Europe PMC PMID:41537239

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41537239
DOI
10.1093/bioinformatics/btag007
License (as archived)
solo-consultazione
Archived
2026-10-08T11:30:05.847Z
SHA-256 of the archived text
f65084528ad025504f0bae25ee7bc9d781560b353a9e1b30dbedb2bb96e11b41
Stable URL of this page
https://metraipolis.com/documento/dc_445ea9d8537b

How to cite

Characterizing clinical toxicity in cancer combination therapies — Europe PMC PMID:41537239 — Europe PMC (en), https://europepmc.org/article/MED/41537239 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_445ea9d8537b (Metraipolis archive dc_445ea9d8537b, sha256 f65084528ad025504f0bae25ee7bc9d781560b353a9e1b30dbedb2bb96e11b41)
BibTeX
@misc{dc445ea9d8537b,
  title = {Characterizing clinical toxicity in cancer combination therapies — Europe PMC PMID:41537239},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41537239},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_445ea9d8537b; sha256 f65084528ad025504f0bae25ee7bc9d781560b353a9e1b30dbedb2bb96e11b41},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41537239. Agents can read the archived copy with the MCP tool read_document.